Summary:
Metroplex Clinical Research Center is conducting a phase 2, open-label, dose-finding study to evaluate the safety, tolerability, and activity of KD025 in subjects with Psoriasis Vulgaris who failed first-line therapy.
Qualified Participants Must:
• Between 18 and 65 years of age
• Have had stable moderate to severe plaque psoriasis for at least 6 months
Qualified Participants May Receive:
Study medication and procedures at no cost and up to $1125.